Cargando…
The Role of V2 Receptor Antagonists in the Treatment of Hyponatremia
Autor principal: | Palmer, Biff F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Electrolyte Metabolism
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741437/ https://www.ncbi.nlm.nih.gov/pubmed/23946759 http://dx.doi.org/10.5049/EBP.2013.11.1.1 |
Ejemplares similares
-
Hyponatremia: A role for vasopressin receptor antagonists?
por: Ramesh, Gourishankar
Publicado: (2018) -
Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V(2)-Receptor Antagonist Tolvaptan
por: Gaglio, Paul, et al.
Publicado: (2012) -
Dose comparison of conivaptan (Vaprisol(®)) in patients with euvolemic or hypervolemic hyponatremia – efficacy, safety, and pharmacokinetics
por: Palmer, Biff F, et al.
Publicado: (2016) -
Vasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses
por: Rondon-Berrios, Helbert, et al.
Publicado: (2017) -
Management Challenges in a Child with Chronic Hyponatremia: Use of V2 Receptor Antagonist
por: Krishnan, Sowmya, et al.
Publicado: (2017)